Video

Dr. Mamounas on Neoadjuvant Chemotherapy for Breast Cancer

Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses the management of neoadjuvant chemotherapy for patients with breast cancer.

Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses the management of neoadjuvant chemotherapy for patients with breast cancer.

Data has been accumulated over the last several years on the effects of neoadjuvant chemotherapy on down-staging the disease, not only in the breast but in the axilla. There are clinical trials demonstrating that neoadjuvant chemotherapy downstages the axillary nodes so it can confer positive nodes to negative nodes. Now physicians can offer sentinel lymph node biopsies, which can potentially turn patients away from having a dissection and reduce the risk of lymphedema and other morbidities.

Neoadjuvant chemotherapy not only reduces the disease burden but also the extent of axillary surgery, Mamounas says.

Related Videos
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center